MagForce Nanotechnologies expands management team
To support 2011 product launch and further developments
The Berlin-based company said these new roles will support the launch of its EU-approved therapy for the treatment of brain tumours and the further development of its Nano-Cancer therapy in additional cancer indications.
Christoph Rehfuess joins MagForce as director of intellectual property. He is a European patent attorney with 12years of experience in the biotech intellectual property field at Medigene. He takes responsibility for patents, trademarks, and technical contracts.
Dirk Kautz takes the role of director of business/corporate development. Prior to joining MagForce, he worked for more than 13 years in the medical devices industry, holding management positions in marketing and corporate development at, among others, Nihon Kohden and Biotronik.
Kajo Wiest joins as director of finance and controlling and brings with him more than 10 years of finance and controlling experience at Jerini.
Stacy Wiedenmann becomes director of investor relations and corporate communications and brings with her over 10 years of experience. She has also worked at Jerini.
The fifth new recruit is Hans Joachim Hutt, who will support the company in the area of medical affairs. The firm said his medical training and more than 20 years of experience at pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks and expand its therapeutic applications.
‘Filling these key company positions is an important step in the transformation of the company from a research and development only business into a commercial company. Additional hiring for the sales and marketing team will be completed by the end of the year,’ said Peter Heinrich, ceo of MagForce.
You may also like
Research & Development
Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform
Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Research & Development
Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption
A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical
Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026
Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment